Granissetrom Kabi (Granisetron Hydrochloride)

Granissetrom Kabi is used clinically to reduce the risk of nausea and vomiting in specific treatment settings.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV).
• Prevention of postoperative nausea and vomiting (PONV).
• Adjunct therapy for patients receiving highly emetogenic chemotherapy.
• Use in combination with other antiemetic agents when recommended by guidelines.
• Management of nausea associated with radiation therapy.
• Use in patients who have experienced breakthrough nausea despite standard prophylaxis.

The safety profile of Granissetrom Kabi includes both frequently observed and less common adverse reactions.

Common

• Headache.
• Constipation.
• Dizziness.
• Fatigue.
• Injection‑site pain or erythema.

Serious

• Anaphylactic reaction.
• Cardiac arrhythmia or severe hypotension.
• Serotonin syndrome (rare).

Before prescribing Granissetrom Kabi, clinicians should consider several precautionary factors to ensure safe use.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with prolonged QT interval or cardiac conduction disorders.
• Evaluate hepatic or renal impairment, as dose adjustment may be required.
• Monitor for signs of serotonin syndrome when combined with serotonergic drugs.
• Consider pregnancy and breastfeeding status; safety data are limited.
• Review concomitant medications that may affect cardiac rhythm.

Granissetrom Kabi can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with other 5‑HT3 antagonists (duplicate antiemetic effect).
• Combination with drugs known to prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid (risk of serotonin syndrome).
• CYP3A4 inhibitors or inducers that may alter granisetron plasma levels.
• Other antiemetics that may increase cardiac risk.